Tag: Prolactinoma

Caberlact 0.25 mg, which contains the active ingredient cabergoline, is a medication used to treat conditions caused by high prolactin levels. While effective, it is known to cause a variety of side effects, ranging from common gastrointestinal and neurological symptoms to rarer, more serious cardiac and psychiatric issues.

Dopamine agonists like cabergoline are the first-line treatment for prolactin-secreting pituitary tumors, a condition affecting millions worldwide. This medication, known for its high efficacy and better tolerability compared to older alternatives, can not only normalize prolactin levels but also cause significant tumor shrinkage. This article explores the specific conditions under which **does cabergoline reduce pituitary tumors** and details its mechanism and practical application.

Hyperprolactinemia, or high prolactin levels, occurs in less than 1% of the general population but can rise to 14% in individuals with certain health conditions. So, what drugs lower prolactin levels? The most common and effective treatments are dopamine agonists.

As a potent and long-acting dopamine receptor agonist, cabergoline is primarily known for its role in treating conditions caused by excessive levels of the hormone prolactin. By mimicking the action of dopamine, cabergoline effectively reduces prolactin secretion from the pituitary gland, addressing a range of health issues in both men and women.

According to research on pharmacovigilance databases, certain medications are disproportionately associated with reports of pituitary tumors, signaling a potential link, though not direct causation. The primary connection revolves around medication-induced hyperprolactinemia, a condition where drugs elevate prolactin levels and thereby increase the risk of developing a prolactin-secreting pituitary tumor, or prolactinoma.